journal article·2026-06

A hypoxia-responsive prodrug for specific drug release and synergistic chemo-photodynamic cancer therapy

Zhen-Kun Sun, Feng-Yan Yao, Wen-Qiang Wu, Yong-Jun Tao, Tian-Jiao Gao, Jian-Yong Liu, Lijing Zheng

Dyes and Pigments· Volume 249
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
3. Current challenges in cancer treatment10.1016/j.clinthera.2016.03.026 ↗
4. Cancer therapy with antibodies10.1038/s41568-024-00690-x ↗
5. Radiopharmaceutical therapy in cancer: clinical advances and challenges10.1038/s41573-020-0073-9 ↗
6. Rational combinations of targeted cancer therapies: background, advances and challenges10.1038/s41573-022-00615-z ↗
7. Photodynamic therapy for cancer10.1038/nrc1071 ↗
8. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
9. Recent advancement in photosensitizers for photodynamic therapy10.1016/j.dyepig.2024.112262 ↗
10. Fluorescent dyes based on rhodamine derivatives for bioimaging and therapeutics: recent progress, challenges, and prospects10.1039/D2CS00799A ↗
11. Recent advances for enhanced photodynamic therapy: from new mechanisms to innovative strategies10.1039/D3SC07006A ↗
12. N-bridging tetra-substituted zinc(II) phthalocyanines with Q-band absorption up to 780 nm and eminent photosensitizing activities for photodynamic therapy10.1016/j.dyepig.2024.112169 ↗
13. Self-assembled ruthenium–amino acid conjugates enable endoplasmic reticulum–nucleus Cascade targeting for cell pyroptosis and DNA destruction10.1002/adma.202508713 ↗
14. A switchable phototherapeutic strategy based on a hypoxia-responsive photosensitizer for heterogeneous tumor ablation10.1016/j.dyepig.2022.110217 ↗
15. A dual-locked activatable phototheranostic probe for biomarker-regulated photodynamic and photothermal cancer therapy10.1002/anie.202202966 ↗
16. Rational design of mesoporous coordination polymer nanophotosensitizers for photodynamic tumor ablation10.1021/acsami.2c22095 ↗
17. An NIR-II photothermally triggered “Oxygen Bomb” for hypoxic tumor programmed Cascade therapy10.1002/adma.202201978 ↗
18. A self-catalytic NO/O2 gas-releasing nanozyme for radiotherapy sensitization through vascular normalization and hypoxia relief10.1002/adma.202403921 ↗
19. Hypoxia-tolerant polymeric photosensitizer prodrug for cancer photo-immunotherapy
20. NIR-II photoacoustic imaging-guided oxygen delivery and controlled release improves photodynamic therapy for hepatocellular carcinoma10.1002/adma.202308780 ↗
21. Activatable nano-photosensitizers for precise photodynamic cancer therapy10.1016/j.ccr.2023.215324 ↗
22. Conquering the hypoxia limitation for photodynamic therapy10.1002/adma.202103978 ↗
23. The current status of photodynamic therapy in cancer treatment10.3390/cancers15030585 ↗
24. Self-disassembling and oxygen-generating porphyrin-lipoprotein nanoparticle for targeted glioblastoma resection and enhanced photodynamic therapy10.1002/adma.202307454 ↗
25. Amphiphilic fluorinated Aza-BODIPY alleviates hypoxia in solid tumors and enhances the photodynamic efficacy for breast cancer10.1016/j.bioorg.2025.109101 ↗
26. Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose10.7150/thno.25409 ↗
27. Lonidamine liposomes to enhance photodynamic and photothermal therapy of hepatocellular carcinoma by inhibiting glycolysis10.1186/s12951-023-02260-z ↗
28. Activatable type I photosensitizer with quenched photosensitization pre and post photodynamic therapy10.1002/anie.202307288 ↗
29. Strategic design of conquering hypoxia in tumor for advanced photodynamic therapy10.1002/adhm.202300530 ↗
30. Precise gliomas therapy: hypoxia-activated prodrugs sensitized by nano-photosensitizers10.1016/j.biomaterials.2022.121770 ↗
31. An activatable phototheranostic probe for anti-hypoxic type I Photodynamic- and immuno-therapy of cancer10.1002/adma.202305243 ↗
32. Two-photon-activated heavy-atom free AIEgen for highly efficient type I photodynamic therapy10.1002/adfm.202410202 ↗
33. Targeting Warburg effect to rescue the suffocated photodynamic therapy: a cancer-specific solution10.1016/j.biomaterials.2023.122017 ↗
34. Bioorthogonal chemistry and illumination controlled programmed size-changeable nanomedicine for synergistic photodynamic and hypoxia-activated therapy10.1016/j.biomaterials.2022.121480 ↗
35. Basic structural modifications for improving the practical properties of BODIPY10.1016/j.ccr.2022.214684 ↗
36. BODIPY as a multifunctional theranostic reagent in biomedicine: self-assembly, properties, and applications10.1002/adma.202207546 ↗
37. Heavy-atom-modulated supramolecular assembly increases antitumor potency against malignant breast tumors via tunable cooperativity10.1002/adma.202004225 ↗
38. A paclitaxel prodrug activatable by irradiation in a hypoxic microenvironment10.1002/anie.202008732 ↗
39. BODIPY-based probes for hypoxic environments10.1016/j.ccr.2023.215041 ↗
40. Hypoxia-responsive nano-photosensitizer anchored by PEGylated BODIPY: a single-laser-driven platform for photo-enhanced synergistic chemo/photodynamic/photothermal cancer therapy10.1021/acs.molpharmaceut.5c00646 ↗
41. Breaking the myth of enzymatic azoreduction10.1021/acschembio.4c00779 ↗
42. Nature-inspired photocatalytic azo bond cleavage with red light10.1021/jacs.3c09837 ↗
43. A hypoxia-activated prodrug conjugated with a BODIPY-based photothermal agent for imaging-guided chemo-photothermal combination therapy10.1021/acsami.2c09071 ↗
44. Bioorthogonal Turn-On BODIPY-peptide photosensitizers for tailored photodynamic therapy10.1002/chem.202001718 ↗
45. Mitochondrion-targeting PEGylated BODIPY dyes for near-infrared cell imaging and photodynamic therapy10.1039/D1TB02393D ↗
46. Enzyme-activated multifunctional prodrug combining site-specific chemotherapy with light-triggered photodynamic therapy10.1021/acs.molpharmaceut.1c00761 ↗